QCI Interpret for Oncology

Managing multiple biomarker therapeutic development

327 views
September 12, 2019
For the past two decades, the paradigm in the field has been “one biomarker, one drug,” leading to the development of many targeted therapies and companion diagnostics. As molecular profiling of various cancer types expands, we imagine the use of multiple biomarkers for a combination therapy, like a targeted therapy and immunotherapy together, or even for a monotherapy.

In this roundtable our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations. Dr. Kelly Sullivan, Solutions Manager, QIAGEN QDI will moderate the discussion with Jeffrey Waldron, Executive Director, Precision Medicine Connective, and Dr. Diana Merino, Science Policy Analyst at Friends of Cancer Research.


Interested in learning more?

Click here


Related videos

QCI Interpret for Oncology

Reduce your test turnaround for large cancer panels

302 views December 31, 2019

Speaker: Sheryl Elkin, CSO, QDI, QIAGEN Interested in learning more? Click here

QCI Interpret for Oncology

Rapid, evidence-based reporting of oncology NGS tests at scale

92 views December 08, 2021

Competing to offer a comprehensive genomic profiling service for solid or...

QCI Interpret for Oncology

Gaining insights with transcriptomic profiling and mechanistic modeling

251 views June 11, 2021

In this webinar, Moritz Schütte, head of next-generation sequencing data...

QCI Interpret for Oncology

Going beyond: Molecular evidence for off-label therapy use

106 views June 02, 2021

Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN...